ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children

Papers of special note have been highlighted as: •• of considerable interest

References

• 1 Sadhasivam S, Chidambaran V, Ngamprasertwong P et al. Race and unequal burden of perioperative pain and opioid related adverse effects in children. Pediatrics 129(5), 832–838 (2012).•• Clinical study showing racial differences in perioperative morphine related pharmacodynamic outcomes in children.
  MedlineGoogle Scholar
• 2 Sadhasivam S, Krekels EH, Chidambaran V et al. Morphine clearance in children: does race or genetics matter? J. Opioid Manag. 8(4), 217–226 (2012).
  MedlineGoogle Scholar
• 3 Fukuda T, Chidambaran V, Mizuno T et al. OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics 14(10), 1141–1151 (2013).•• Our previous clinical study demonstrating OCT1 to be a significant contributor to morphine's clearance in children.
  CASGoogle Scholar
• 4 Thorn CF, Klein TE, Altman RB. Codeine and morphine pathway. Pharmacogenet. Genomics 19(7), 556–558 (2009).
  Medline CASGoogle Scholar
• 5 Sawyer MB, Innocenti F, Das S et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73(6), 566–574 (2003).
  Medline CASGoogle Scholar
• 6 Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin. Exp. Pharmacol. Physiol. 27(7), 524–528 (2000).
  Medline CASGoogle Scholar
• 7 Grisk O, Schlueter T, Steinbach A et al. Effects of generalized and kidney specific Mrp2 (ABCC2) deficiency on renal elimination of PAH and morphine-6-glucuronide. FASEB J. 21, 758–711 (2007).
  Google Scholar
• 8 Huwyler J, Drewe J, Klusemann C, Fricker G. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br. J. Pharmacol. 118(8), 1879–1885 (1996).
  Medline CASGoogle Scholar
• 9 Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin. Pharmacol. Ther. 74(6), 543–554 (2003).
  Medline CASGoogle Scholar
• 10 Lotsch J, Schmidt R, Vetter G et al. Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J. Neurochem. 83(2), 241–248 (2002).
  Medline CASGoogle Scholar
• 11 Tzvetkov MV, Dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmöller J. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem. Pharmacol. 86(5), 666–678 (2013). ••First in vitro study showing OCT1 effects on morphine uptake.
  Medline CASGoogle Scholar
• 12 Van De Wetering K, Zelcer N, Kuil A et al. Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol. Pharmacol. 72(2), 387–394 (2007).
  Medline CASGoogle Scholar
• 13 Xie R, Hammarlund-Udenaes M, De Boer AG, De Lange EC. The role of P-glycoprotein in blood–brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br. J. Pharmacol. 128(3), 563–568 (1999).
  Medline CASGoogle Scholar
• 14 Zelcer N, Van De Wetering K, Hillebrand M et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc. Natl Acad. Sci. USA 102(20), 7274–7279 (2005).
  Medline CASGoogle Scholar
• 15 Lang T, Hitzl M, Burk O et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 14(3), 155–164 (2004).
  Medline CASGoogle Scholar
• 16 Gradhand U, Tegude H, Burk O, Eichelbaum M, Fromm MF, Konig J. Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene. Life Sci. 80(16), 1490–1494 (2007).
  Medline CASGoogle Scholar
• 17 Puranik YG, Birnbaum AK, Marino SE et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 14(1), 35–45 (2013).
  CASGoogle Scholar
• 18 Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet. Genomics 18(4), 357–365 (2008).
  Medline CASGoogle Scholar
• 19 Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 83(4), 559–566 (2008).
  Medline CASGoogle Scholar
• 20 Gong XD, Wang JY, Liu F et al. Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. Asian Pac. J. Cancer Prev. 14(5), 2937–2943 (2013).
  MedlineGoogle Scholar
• 21 Clavijo CF, Hoffman KL, Thomas JJ et al. A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 400(3), 715–728 (2011).
  Medline CASGoogle Scholar
• 22 Meineke I, Freudenthaler S, Hofmann U et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br. J. Clin. Pharmacol. 54(6), 592–603 (2002).
  Medline CASGoogle Scholar
• 23 Skarke C, Jarrar M, Schmidt H et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13(11), 651–660 (2003).
  Medline CASGoogle Scholar
• 24 Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303–332 (2008).
  Medline CASGoogle Scholar
• 25 Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 7(2), E475–E487 (2005).
  MedlineGoogle Scholar
• 26 Hanna MH, Peat SJ, Knibb AA, Fung C. Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br. J. Anaesth. 66(1), 103–107 (1991).
  Medline CASGoogle Scholar
• 27 Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML. Limited Phase I study of morphine-3-glucuronide. J. Pharm. Sci. 90(11), 1810–1816 (2001).
  Medline CASGoogle Scholar
• 28 Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth. 92(2), 208–217 (2004). •• Pharmacokinetic model of morphine capturing maturation effects during development.
  Medline CASGoogle Scholar
• 29 Anderson BJ, Pearce S, McGann JE, Newson AJ, Holford NH. Investigations using logistic regression models on the effect of the LMA on morphine induced vomiting after tonsillectomy. Pediatr Anaesth. 10(6), 633–638 (2000).
  Medline CASGoogle Scholar
• 30 Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 11(3), 558–569 (2009).
  MedlineGoogle Scholar
• 31 Campa D, Vodicka P, Pardini B et al. Could polymorphisms in ATP-binding cassette C3/multidrug resistance associated protein 3 (ABCC3/MRP3) modify colorectal cancer risk? Eur. J. Cancer 44(6), 854–857 (2008).
  Medline CASGoogle Scholar
• 32 Branford R, Droney J, Ross JR. Opioid genetics: the key to personalized pain control? Clin. Genet. 82(4), 301–310 (2012).
  Medline CASGoogle Scholar
• 33 Cohen M, Sadhasivam S, Vinks AA. Pharmacogenetics in perioperative medicine. Curr. Opin. Anaesthesiol. 25(4), 419–427 (2012).
  Medline CASGoogle Scholar
• 34 Sadhasivam S, Myer CM 3rd. Preventing opioid-related deaths in children undergoing surgery. Pain Med. 13(7), 982–983; author reply 984 (2012).
  MedlineGoogle Scholar
• 35 Eissing T, Lippert J, Willmann S. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. Mol. Diagn. Ther. 16(1), 43–53 (2012).
  Medline CASGoogle Scholar
• 36 Mazak K, Hosztafi S, Racz A, Noszal B. Structural and physicochemical profiling of morphine and related compounds of therapeutic interest. Mini Rev. Med. Chem. 9(8), 984–995 (2009).
  Medline CASGoogle Scholar
• 37 Scheffer GL, Kool M, De Haas M et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. 82(2), 193–201 (2002).
  Medline CASGoogle Scholar
• 38 Krekels EH, Johnson TN, Den Hoedt SM et al. From Pediatric covariate model to semiphysiological function for maturation: part II– sensitivity to physiological and physicochemical properties. CPT Pharmacometrics Syst. Pharmacol. 1, e10 (2012).
  Medline CASGoogle Scholar
• 39 Drewe J, Ball HA, Beglinger C et al. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br. J. Clin. Pharmacol. 50(3), 237–246 (2000).
  Medline CASGoogle Scholar
• 40 Jimenez N, Seidel K, Martin LD, Rivara FP, Lynn AM. Perioperative analgesic treatment in Latino and non-Latino pediatric patients. J. Health Care Poor Underserved 21(1), 229–236 (2010).
  MedlineGoogle Scholar
• 41 Fujita K, Ando Y, Yamamoto W et al. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother. Pharmacol. 65(2), 251–258 (2010).
  Medline CASGoogle Scholar
• 42 Hunt A, Joel S, Dick G, Goldman A. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. J. Pediatr. 135(1), 47–55 (1999).
  Medline CASGoogle Scholar
• 43 Holthe M, Klepstad P, Zahlsen K et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. 58(5), 353–356 (2002).
  Medline CASGoogle Scholar
• 44 Lotsch J, Stockmann A, Kobal G et al. Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin. Pharmacol Ther. 60(3), 316–325 (1996).
  Medline CASGoogle Scholar
• 45 Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab. Dispos. 36(4), 688–694 (2008).
  Medline CASGoogle Scholar